Reply: Tofacitinib is a step forward for management of patients with interstitial lung disease associated with anti-MDA5-positive dermatomyositis

Affiliations

¹ Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China ye_shuang2000@163.com.

Comment

Wanlong Wu et al. Eur Respir J. 2025.

. 2025 Jul 14;66(1):2500699.

doi: 10.1183/13993003.00699-2025. Print 2025 Jul.

¹ Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China ye_shuang2000@163.com.

No abstract available

Conflict of interest statement

Conflict of interest: The authors have no potential conflicts of interest to disclose with regard to the work.

Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study.
Wu W, Guo B, Sun W, Chen D, Xu W, Chen Z, Fu Y, Ye Y, Lyu X, Xue Z, Wang K, Zhao J, Xie C, Chen Y, Ye C, Dai M, Fan W, Li J, Wang X, Xue Y, Wan W, Sun L, Wu H, Luo Q, Han Q, Fu Q, Ye S. Wu W, et al. Eur Respir J. 2025 May 22;65(5):2401488. doi: 10.1183/13993003.01488-2024. Print 2025 May. Eur Respir J. 2025. PMID: 39884766 Free PMC article.